345 related articles for article (PubMed ID: 35719979)
1. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
Wang J; He Y; Zhang B; Lv H; Nie C; Chen B; Xu W; Zhao J; Cheng X; Li Q; Tu S; Chen X
Front Oncol; 2022; 12():924149. PubMed ID: 35719979
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Li L; Liu F; Fan X; Yang J; Yang Y; Zhao Y; Guan W; Liu B
Cancer Manag Res; 2022; 14():2007-2015. PubMed ID: 35747712
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer.
Gao L; Tang L; Li X; Peng J; Hu Z; Liu B
Anticancer Drugs; 2024 Mar; 35(3):277-283. PubMed ID: 37948350
[TBL] [Abstract][Full Text] [Related]
5. Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study.
Nie C; Lv H; Liu Y; Chen B; Xu W; Wang J; Chen X
Front Oncol; 2021; 11():741865. PubMed ID: 34631579
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
[TBL] [Abstract][Full Text] [Related]
7. PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series.
Tan S; Yu J; Huang Q; Zhou N; Gou H
Front Oncol; 2022; 12():1006075. PubMed ID: 36465365
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.
Zhao Z; Yin MM; Zhao WF; Wang CJ
Medicine (Baltimore); 2023 Aug; 102(33):e34794. PubMed ID: 37603519
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
Zhang L; Wang W; Ge S; Li H; Bai M; Duan J; Yang Y; Ning T; Liu R; Wang X; Ji Z; Wang F; Zhang H; Ba Y; Deng T
BMC Cancer; 2023 Mar; 23(1):211. PubMed ID: 36872337
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial.
Wang Y; Zhao J; Liang H; Liu J; Huang S; Zou G; Huang X; Lan C
EClinicalMedicine; 2023 Nov; 65():102274. PubMed ID: 38106561
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Katsaounis P; Kotsakis A; Kentepozidis N; Polyzos A; Bakogeorgos M; Koinis F; Vamvakas L; Vardakis N; Kalbakis K; Boukovinas I; Varthalitis II; Prinarakis E; Georgoulias V; Souglakos J
Ann Gastroenterol; 2018; 31(1):65-70. PubMed ID: 29333068
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract][Full Text] [Related]
17. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Yin C; Zou GR; He Y; Li J; Yan HW; Su Z; Cao XL; Li XB
J Thorac Dis; 2023 Apr; 15(4):1838-1847. PubMed ID: 37197501
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
Wang Y; Zhao J; Yu H; Wang J; Zhang N; Cao B
J Cancer Res Ther; 2021 Nov; 17(5):1234-1240. PubMed ID: 34850772
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.
Fang X; Zhu N; Zhong C; Wang L; Li J; Weng S; Hu H; Dong C; Li D; Song Y; Xu D; Wang J; Sun L; Wang J; Wang Z; Cao H; Liao X; Yu N; Xiao Q; Mi M; Zhang S; Ding K; Yuan Y
EClinicalMedicine; 2023 Aug; 62():102123. PubMed ID: 37554125
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
Xiang J; Gong W; Sun P; Wang X; Liu A
J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
